01—Abstract
Summary
Summary of the 8-K filed June 22, 2026. Cited figures are marked; the original filing is the authoritative source.
Revolution Medicines, Inc. (RVMD) filed this Form 8-K reporting two items: a leadership transition and the results of its annual meeting of stockholders held June 18, 2026.
Steve Kelsey, M.D., FRCP, FRCPath, informed the Company on June 18, 2026 of his intent to retire effective January 4, 2027. He will move from his role as president, research and development to senior advisor to the chief executive officer effective July 1, 2026. The Company contemplates appointing him to its Board of Directors effective upon his retirement, subject to Board approval.
He will be eligible for certain benefits under the Company's retirement policy for equity awards. At the annual meeting, stockholders elected Alexis Borisy and Mark A. Goldsmith, M.D., Ph.D. as Class III directors to serve until the 2029 annual meeting.
Stockholders ratified PricewaterhouseCoopers LLP as the independent registered public accounting firm for the fiscal year ending December 31, 2026, and approved, on an advisory basis, the compensation of the named executive officers. Of 212,592,561 shares outstanding and entitled to vote as of the April 23, 2026 record date, Borisy received 127,181,172 votes for and 33,660,532 withheld, and Goldsmith received 157,681,628 votes for and 3,160,076 withheld. On the say-on-pay proposal, 155,110,825 shares voted for, 5,554,146 against, and 176,733 abstained.
The filing is largely administrative and contains no financial results, guidance, or clinical data. The key forward-looking elements concern the timing of Dr. Kelsey's retirement, his advisory role, and the possible Board appointment, none of which is assured.
02—Key points
Key Highlights
- Steve Kelsey, M.D., president of research and development, will retire effective January 4, 2027, and becomes senior advisor to the CEO effective July 1, 2026.
- The Company contemplates appointing Dr. Kelsey to the Board effective upon his retirement, subject to Board approval.
- Dr. Kelsey will be eligible for certain benefits under the Company's retirement policy for equity awards.
- Stockholders re-elected Class III directors Alexis Borisy and Mark A. Goldsmith, M.D., Ph.D., each to serve until the 2029 annual meeting; Goldsmith received 157,681,628 votes for and Borisy 127,181,172.
- Stockholders ratified PricewaterhouseCoopers LLP as independent registered public accounting firm for fiscal year 2026, with 181,309,783 votes for and 206,306 against.
- Stockholders approved, on a non-binding advisory basis, the compensation of named executive officers, with 155,110,825 votes for and 5,554,146 against.
- The annual meeting was held June 18, 2026, with 212,592,561 common shares outstanding and entitled to vote as of the April 23, 2026 record date.
03—Questions
Frequently Asked Questions
Who is leaving the leadership team, and what is his new role?
Steve Kelsey, M.D., FRCP, FRCPath, is retiring from his role as president, research and development. He will become senior advisor to the chief executive officer effective July 1, 2026, and his employment retirement is effective January 4, 2027.
Will Dr. Kelsey remain involved with the Company after he retires?
The Company contemplates appointing him to its Board of Directors effective upon his retirement on January 4, 2027, but this is subject to Board approval and is not assured.
What did stockholders decide at the June 18, 2026 annual meeting?
Stockholders elected Alexis Borisy and Mark A. Goldsmith, M.D., Ph.D. as Class III directors to serve until the 2029 annual meeting, ratified PricewaterhouseCoopers LLP as auditor for 2026, and approved the advisory vote on executive compensation.
Did stockholders support executive compensation?
Stockholders approved, on a non-binding advisory basis, the compensation of the named executive officers, with 155,110,825 votes for, 5,554,146 against, and 176,733 abstentions, as disclosed in the proxy statement.
What risks does the Company identify regarding these changes?
The Company notes that Dr. Kelsey's retirement, transition, or continued service may not occur on the anticipated timeline or terms, the Board appointment may not occur, and the Company may face difficulty attracting, retaining, and transitioning key personnel. Risks are described in the Company's Form 10-Q filed May 6, 2026.
04—Continue